Valneva's 15min chart shows Bollinger Bands expanding upward, bullish Marubozu pattern.

Valneva's 15-minute chart has exhibited a notable trend reversal, as evidenced by the expansion of Bollinger Bands upward and the presence of a bullish Marubozu at 10/09/2025 11:00. This indicates that market momentum is predominantly driven by buying activity, with buyers exerting control over the market. As a result, it is likely that bullish momentum will continue to prevail.

Valneva SE (NASDAQ: VALN), a French vaccine developer, saw its shares fall significantly on September 10, 2025, amidst delays in releasing Phase 3 data for its Lyme disease vaccine and downward revisions to its 2025 financial outlook. The company's stock experienced a notable trend reversal, as indicated by the expansion of Bollinger Bands upward and the presence of a bullish Marubozu at 10/09/2025 11:00, suggesting a shift in market momentum towards buying activity Valneva falls after Lyme disease vaccine data delay, outlook cut^[1].

The delay in the Phase 3 data release for the Lyme disease vaccine, originally expected in late 2025, has now been pushed back to the first half of 2026. This setback has prompted Valneva to revise its annual revenue projections downward to €165-180 million from the previously anticipated €180-190 million. Additionally, the company has reduced its research and development spending to €80-90 million from the earlier forecast of €90-100 million Valneva falls after Lyme disease vaccine data delay, outlook cut^[1].

The challenges faced by Valneva are not limited to the Lyme disease vaccine. The company also experienced a setback with its chikungunya vaccine, Ixchiq, which had its marketing authorization revoked by the U.S. FDA over safety concerns. This has led to a reduction in full-year sales projections from €170-180 million to €155M-€170M and a decrease in total revenue guidance from €180M-€190M to €165M-€180M Valneva lowers 2025 financial outlook due to loss of Ixchiq vaccine marketing^[2].

Valneva has responded to these challenges by securing a new debt facility of up to $500 million with Pharmakon Advisors, LP. The initial tranche of $215 million will be used to repay existing debt, while the remaining $285 million can be drawn in the future to support business development. The company has also emphasized that its commercial operations remain on track to deliver positive cash flow Valneva Shares Slide After FDA Suspension Prompts Guidance Revision^[3].

Despite these setbacks, Valneva remains optimistic about the progress of its Phase 3 trial for the Lyme disease vaccine, which is co-developed with Pfizer (NYSE: PFE). The companies still intend to file regulatory submissions in 2026, with a potential market launch in the second half of 2027, pending approval Valneva Shares Slide After FDA Suspension Prompts Guidance Revision^[3].

In summary, Valneva's recent financial struggles, driven by vaccine delays and regulatory setbacks, have led to a significant drop in its stock price. However, the company's strategic moves, such as securing new financing and maintaining the progress of its vaccine pipeline, suggest a commitment to navigating these challenges and positioning itself for future growth.